% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Daskalakis:178299,
      author       = {M. Daskalakis and A. Feller and J. Noetzli and N. Bonadies
                      and V. Arndt$^*$ and G. M. Baerlocher and The Nicer Working
                      Group},
      title        = {{P}otential to {I}mprove {T}herapy of {C}hronic {M}yeloid
                      {L}eukemia ({CML}), {E}specially for {P}atients with {O}lder
                      {A}ge: {I}ncidence, {M}ortality, and {S}urvival {R}ates of
                      {P}atients with {CML} in {S}witzerland from 1995 to 2017.},
      journal      = {Cancers},
      volume       = {13},
      number       = {24},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2021-03246},
      pages        = {6269},
      year         = {2021},
      abstract     = {Tyrosine kinase inhibitors (TKI) substantially improved
                      chronic myeloid leukemia (CML) prognosis. We aimed to
                      describe time period- and age-dependent outcomes by
                      reporting real-world data of CML patients from
                      Switzerland.Population-based incidence, mortality, and
                      survival were assessed for four different study periods and
                      age groups on the basis of aggregated data from Swiss
                      Cantonal Cancer Registries.A total of 1552 new CML cases
                      were reported from 1995 to 2017. The age-standardized rate
                      (ASR) for the incidence remained stable, while the ASR for
                      mortality decreased by $50-80\%,$ resulting in a five-year
                      RS from $36\%$ to $74\%$ over all four age groups.
                      Importantly, for patients <60 years (yrs), the five-year RS
                      increased only in earlier time periods up to $92\%,$ whereas
                      for older patients (+80 yrs), the five-year RS continued to
                      increase later, however, reaching only $53\%$ until
                      2017.This is the first population-based study of CML
                      patients in Switzerland confirming similar data compared to
                      other population-based registries in Europe. The RS
                      increased significantly in all age groups over the last
                      decades after the establishment of TKI therapy.
                      Interestingly, we found a more prominent increase in RS of
                      patients with older age at later observation periods
                      $(45\%)$ compared to patients at younger age $(10\%),$
                      implicating a greater benefit from TKI treatment for elderly
                      occurring with delay since the establishment of TKI therapy.
                      Our findings suggest more potential to improve CML therapy,
                      especially for older patients.},
      keywords     = {CML (Other) / incidence (Other) / mortality (Other) /
                      relative survival (Other) / tyrosine kinase inhibitor
                      (Other)},
      cin          = {C071},
      ddc          = {610},
      cid          = {I:(DE-He78)C071-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34944892},
      doi          = {10.3390/cancers13246269},
      url          = {https://inrepo02.dkfz.de/record/178299},
}